SCHEMBL452910

SCHEMBL452910

C1=CC2Sc3ccccc3C2C=C1

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.34
MAOA P21397 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13710984 0.77 ALOX5 (0.38) ALOX5MAOA
SCHEMBL12199688 0.77 ALOX5 (0.43) ALOX5MAOA
SCHEMBL12175665 0.73 ALOX5 (0.33) ALOX5MAOA
SCHEMBL23784132 0.73 MAOA (0.51) MAOA
SCHEMBL21693585 0.73 ALOX5 (0.31) ALOX5MAOA
SCHEMBL4096667 0.73 ALOX5 (0.37) ALOX5MAOA
SCHEMBL23450698 0.73 ALOX5 (0.31) ALOX5MAOA
SCHEMBL19114788 0.73 MAOA (0.34) MAOA
SCHEMBL12993299 0.73 MAOA (0.34) MAOA
SCHEMBL13890882 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113861128-A Polymerizable compound and optically anisotropic body 江苏创拓新材料有限公司 2021-12-31 CN claimed
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2026-04-14 US disclosed
US-20260083735-A1 ABHD6 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2026-03-26 US disclosed
EP-4596555-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2025-08-06 EP disclosed
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2024-08-15 US disclosed
US-11981682-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2024-05-14 US disclosed
WO-2024071398-A1 ABHD6 ANTAGONIST 小野薬品工業株式会社 2024-04-04 WO disclosed
EP-4317153-A1 ABHD6 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2024-02-07 EP disclosed
CN-114560828-B Polymerizable compound and optically anisotropic body formed therefrom 江苏创拓新材料有限公司 2024-01-26 CN disclosed
EP-3238286-B1 MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2024-01-17 EP disclosed
EP-1378509-A1 DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-01-07 EP disclosed
EP-1346985-A1 PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-08 US disclosed
EP-1306373-A1 3,4-DIHYDROISOQUINOLINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2003-05-02 EP disclosed
EP-1236726-A1 TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-04 EP disclosed
EP-1234834-A1 1,3,4-OXADIAZOLIN-2-ONE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-08-28 EP disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed
EP-0527635-A2 Process for the catalytic hydrotreatment of petroleum feeds for the selective removal of sulfur and nitrogen EXXON RESEARCH AND ENGINEERING COMPANY (US) 1993-02-17 EP disclosed
US-5186818-A Hydrodesulfurizatioin and/or hydrodenitrogenation using transition metal compounds in stacked beds having controlled rim to edge ratios EXXON RESEARCH AND ENGINEERING COMPANY (US) 1993-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087831-A1 1,3,4-Oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient SERPINB1, ELANE, MMP8 ALOX5 530/4885MAOA 2618/4885
US-20240270755-A1 SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS ABHD6, ABHD16A, PITHD1 ALOX5 3069/4885MAOA 2511/4885
US-11981682-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, PITHD1 ALOX5 3075/4885MAOA 2505/4885
US-12600730-B2 Substituted cyclopenta[c]pyrroles as ABHD6 antagonists ABHD6, ABHD16A, HDHD5 ALOX5 3159/4885MAOA 2440/4885
US-20260083735-A1 ABHD6 ANTAGONIST ABHD6, ABHD16A, ABHD12 ALOX5 3092/4885MAOA 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.